Abstract
Active surveillance (AS) is an important management option for men with low-risk, clinically localized prostate cancer. The clinical parameters for patient selection and definition of progression for AS protocols are evolving as data from several large cohorts matures. Vital to this process is the critical role pathologic parameters play in identifying appropriate candidates for AS. These findings need to be reproducible and consistently reported by surgical pathologists. This report highlights the importance of accurate pathology reporting as a critical component of these protocols.
Similar content being viewed by others
References
Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR, Investigators CPSURE (2004) The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 171:1393–1401
Albertsen PC, Hanley JA, Fine J (2005) 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095–2101
Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117–1123
Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, Klein EA, Wood DP, Scardino PT (2009) Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 27:4300–4305
Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94:981–990
Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO (2004) Natural history of early, localized prostate cancer. JAMA 291:2713–2719
McGregor M, Hanley JA, Boivin JF, McLean RG (1998) Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 159:1368–1372
Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O’Leary M, Walker-Corkery E, Yao SL (2009) Outcomes of localized prostate cancer following conservative management. JAMA 302:1202–1209
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71
Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D’Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM, AUA Prostate Cancer Clinical Guideline Update Panel (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177:2106–2131
Network NCC (2010) NCCN clinical practice guidelines in oncology: prostate cancer. Available at: www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
Dall’Era MA, Cooperberg MR, Chan JM, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ (2008) Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112:1650–1659
Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R (2012) Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res 18:5471–5478
Ganz PABJ, Burke W, Col NF, Corso PS, Dodson E, Hammond ME, Kogan BA, Lynch CF, Newcomer L, Seifter EJ, Tooze JA, Viswanath K, Wessells H (2011) National institutes of health state-of-the-science conference statement: role of active surveillance in the management of men with localized prostate cancer. NIH Consens State Sci Statement 28:1–27
Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, et al. (2014) The critical role of the pathologist in determining eligibility for active surveillance as a management options in patients with prostate cancer: consensus statement with recommendations supported by the college of american pathologist, international society of urologic pathologist, association of directors of anatomic and surgical pathology, the New Zealand society of pathologists and the prostate cancer foundation. Arch Pathol Lab Med
Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ (2013) Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63:597–603
Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131
Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB (2011) Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 29:2185–2190
Montironi R, Lopez-Beltran A, Mazzucchelli R, Scarpelli M, Galosi AB, Cheng L (2014) Contemporary update on pathology-related issues on routine workup of prostate biopsy: sectioning, tumor extent measurement, specimen orientation, and immunohistochemistry. Anal Quant Cytol Histol 36:61–70
Montironi R, Scarpelli M, Mazzucchelli R, Cheng L, Lopez-Beltran A, Montorsi F (2012) Extent of cancer of less than 50 % in any prostate needle biopsy core: how many millimeters are there? Eur Urol 61:751–756
Brimo F, Vollmer RT, Corcos J, Kotar K, Begin RL, Humphrey PA, Bismar TA (2008) Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. Histopathology 53:177–183
Karram S, Trock BJ, Netto GJ, Epstein JI (2011) Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. Am J Surg Pathol 35:1351–1355
Schultz L, Maluf CE, da Silva RC, Falashi Rde H, da Costa MV, Schultz MI (2013) Discontinuous foci of cancer in a single core of prostatic biopsy: when it occurs and performance of quantification methods in a private-practice setting. Am J Surg Pathol 37:1831–1836
Epstein JI (2010) An update of the Gleason grading system. J Urol 183:433–440
Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446–1452
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study is supported by The College of American Pathologists, International Society of Urologic Pathology, Association of Directors of Anatomic and Surgical Pathology, The New Zealand Society of Pathologists, and The Prostate Cancer Foundation.
Appendix
Appendix
-
Team 1: Clinical perspective on active surveillance: Daniel Lin, John Gore (team leads), John Nacey, Ballentine Carter, Laurence Klotz, Anthony Zietman, and Stuart Holden
-
Team 2: Tumor quantification and other pathologic parameters: John Srigley, Hema Samaratunga (team leads), Rodolfo Montironi, Peter Humphrey, and Andrew Evans
-
Team 3: Gleason grading of prostate cancer: Lars Egevad (team lead), Jonathan Epstein, Brett Delahunt, Mahul Amin, Jesse McKenney, Dan Berney, and Thomas Wheeler
-
Team 4: Ancillary molecular diagnostic tests: Mark Rubin (team lead), Arul Chinnaiyan, Lawrence True, and Beatrice Knudsen
Rights and permissions
About this article
Cite this article
Montironi, R., Hammond, E.H., Lin, D.W. et al. Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Arch 465, 623–628 (2014). https://doi.org/10.1007/s00428-014-1668-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-014-1668-5